Phase II Trials in Journal of Clinical Oncology
- 1 July 2009
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (19), 3073-3076
- https://doi.org/10.1200/jco.2009.23.1811
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Optimising the design of phase II oncology trials: The importance of randomisationEuropean Journal Of Cancer, 2008
- Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?Journal of Clinical Oncology, 2008
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung CancerClinical Cancer Research, 2008
- Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening TrialsJournal of Clinical Oncology, 2005
- Randomized Phase II Trials: What Does Randomization Gain?Journal of Clinical Oncology, 2005
- Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment TrialsJournal of Clinical Oncology, 2005
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- The Ethics of Early Stopping Rules: Who Is Protecting Whom?Journal of Clinical Oncology, 2004
- Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?Journal of Clinical Oncology, 2001